Gruppo Oncologico del Nord-Ovest
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 1987-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://gonogroup.org/
Clinical Trials
48
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 280
- Registration Number
- NCT07094893
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
- Conditions
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Interventions
- Drug: 5-FU (5-fluorouracil)
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 340
- Registration Number
- NCT06897644
- Locations
- 🇮🇹
Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy
🇮🇹University Hospital Consorziale Policlinico, Bari, Italy
🇮🇹Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
- Interventions
- Drug: Cetuximab/avelumab
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 67
- Registration Number
- NCT06869473
- Locations
- 🇮🇹
Irccs Humanitas Research Hospital, Rozzano, Milano, Italy
🇮🇹Ospedale Oncologico "A. Businco" ARNAS BROTSU, Cagliari, Italy
🇮🇹Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco, Catania, Italy
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 238
- Registration Number
- NCT06733038
- Locations
- 🇮🇹
Azienda USL Toscana Nord Ovest, Livorno, LI, Italy
🇮🇹Azienda Ospedaliero Universitaria di Modena, Modena, MO, Italy
🇮🇹Fondazione Poliambulanza, Istituto Ospedaliero, Brescia, BS, Italy
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 16
- Registration Number
- NCT06578559
- Locations
- 🇮🇹
L'Azienda Ospedaliero Universitaria di Cagliari, Monserrato, CA, Italy
🇮🇹Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst, Meldola, FC, Italy
🇮🇹Fondazione Casa Sollievo Della Sofferenza - Irccs, San Giovanni Rotondo, FG, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next